Spectrum Pharmaceuticals Highlights 19 Abstracts At The 54th Annual Meeting Of The American Society Of Hematology (ASH), Atlanta, Georgia, December 8-11, 2012

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced key presentations of clinical and scientific data at the 54th Annual Meeting of the American Society of Hematology (ASH), being held in Atlanta, Georgia, from December 8-11, 2012. The presentations include two oral presentations and 10 poster presentations for ZEVALIN® (ibritumomab tiuxetan) injection for intravenous use, three poster presentations for FOLOTYN® (pralatrexate injection), and four poster presentations for belinostat, a novel histone deacetylase (HDAC) inhibitor.

“Nearly 20 presentations at ASH will feature clinical and scientific data for Spectrum’s commercial products, ZEVALIN and FOLOTYN, as well as our late-stage drug candidate, belinostat,” said Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. “The ZEVALIN-related abstracts demonstrate its use in a multitude of diverse settings and potential indications in which this product is being tested, including transplantation, its use in elderly patients, in frontline treatment and in the treatment of relapsed/refractory disease, as well as in new drug combinations. The FOLOTYN-related abstracts include presentations on new, synergistic combinations with other approved agents and in difficult-to-treat indications, such as HTLV-1-induced leukemia/lymphoma, while belinostat-related presentations are studying new combinations and indications, such as in refractory AML/MDS, as well as research on this promising drug candidate’s mechanism of action.”

For more information about the ASH annual meeting and for a complete list of abstracts, please refer to the conference Web site at https://ash.confex.com/ash/2012/webprogram/start.html.

The following are key ZEVALIN-related abstracts being presented at the ASH meeting:

Abstract #		Type		Title		First Author		Date/Time Location
1978		Poster		Autologous Stem Cell Transplantation with Yttriumm-90-Ibritumomab Tiuxetan (Zevalin) Plus BEAM Conditioning in Patients with Refractory Non-Hodgkin Diffuse Large B-Cell Lymphoma: Results of a Prospective, Multicenter, Phase II Clinical Trial		Briones		Saturday, Dec. 8 5:30 PM-7:30 PM   Hall B1-B2
2742		Poster		RIT with 90Y Ibritumomab Tiuxetan in Patients with Non-Hodgkin Lymphoma Over 65 Years		Andrade		Sunday, Dec. 9, 6:00 PM-8:00 PM   Hall B1-B2
2687		Poster		A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402)		Witzig		Sunday, Dec. 9, 6:00 PM-8:00 PM   Hall B1-B2
2726		Poster		90-Yttrium Ibritumomab Tiuxetan (Zevalin) and BEAM Chemotherapy (Z-BEAM) Vs BEAM for Autologous Stem Cell Transplantation in Lymphoma: Toxicity and Long Term Outcome From a Retrospective Multicentric Study of 123 Patients		Terriou		Sunday, Dec. 9, 6:00 PM-8:00 PM   Hall B1-B2
2729		Poster		Rituximab-PECC Induction Followed by 90y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or After ASCT: Preliminary Results From a Phase II HOVON Study		Lugtenburg		Sunday, Dec 9, 6:00 PM-8:00 PM   Hall B1-B2
2753		Poster		Phase I Trial of Combination Therapy with 90y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin’s Lymphoma, Final Report		Borghaei		Sunday, Dec. 9, 6:00 PM-8:00 PM   Hall B1-B2
3019		Poster		Collection of Hematopoietic Stem Cells After Previous Exposure to Ittrium-90 Ibritumumab Tiuxetan (Zevalin) Is Feasible and Does Not Impair Autologous Stem Cell Transplantation Outcome in Follicular Lymphoma		Derenzini		Sunday, Dec. 9, 6:00 PM-8:00 PM   Hall B1-B2
747		Oral		Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin		Kolstad		Monday, Dec. 10, 5:00 PM   B312-B313a
3657		Poster		Short Course of Bendamustine and Rituximab Followed by 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naïve Follicular Lymphoma: Early Results of "Fol-Brite"		Lansigan		Monday, Dec. 10, 6:00 PM-8:00 PM   Hall B1-B2
3648		Poster		FDG-PET/CT Early After 90Y-Ibritumomab Tiuxetan Therapy Predicts Outcome in Relapsed or Refractory Indolent B-Cell Lymphoma		Okada		Monday, Dec. 10, 6:00 PM-8:00 PM   Hall B1-B2
3681		Poster		Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90 Υ-Radioimmunotherapy and Maintenance Rituximab		Berinstein		Monday, Dec. 10, 6:00 PM-8:00 PM   Hall B1-B2
812		Oral		Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High Dose Therapy with Stem-Cell Transplantation in Poor Risk Patients with Diffuse Large B-Cell Lymphoma		Fruchart		Monday, Dec. 10 6:30 PM   B312-B313a

The following are key FOLOTYN-related abstracts being presented at the ASH meeting:

Abstract #		Type		Title		First Author		Location
2735		Poster		Pralatrexate in Relapsed/Refractory HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia: A New York City Multi-Institutional Experience		Lunning		Sunday, Dec. 9, 6:00 PM-8:00 PM   Hall B1-B2
2758		Poster		Novel Imaging Modalities in Innovative Xenograft Mouse Models of T-Cell Lymphoma Confirm Marked Synergy of Romidepsin and Pralatrexate		Jain		Sunday, Dec. 9, 6:00 PM-8:00 PM   Hall B1-B2
3660		Poster		Cutaneous Toxicity Associated with Pralatrexate in Cutaneous and Peripheral T-Cell Lymphoma		Parker		Monday, Dec. 10, 6:00 PM-8:00 PM   Hall B1-B2

The following are key belinostat-related abstracts being presented at the ASH conference:

Abstract #		Type		Title		First Author		Location
1359		Poster		Mechanisms of Sensitivity and Resistance to Histone Deacetylase Inhibitors in Diffuse Large B-Cell Lymphoma		Tula-Sanchez		Saturday, Dec. 8, 5:30 PM-7:30 PM   Hall B1-B2
2725		Poster		Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease		Amengual		Sunday, Dec. 9, 6:00 PM-8:00 PM   Hall B1-B2
3588		Poster		Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update		Holkova		Monday, Dec. 10, 6:00 PM-8:00 PM   Hall B1-B2
3891		Poster		Inhibition of Histone Deacetylase Activity Compromises Homologous Recombination Repair and Increases Sensitivity of Chemo-Resistant Chronic Lymphocytic Leukemia Cells to Olaparib		Agathanggelou		Monday, Dec. 10, 6:00 PM-8:00 PM   Hall B1-B2

About Non-Hodgkin's Lymphoma

According to the National Cancer Institute ( www.cancer.gov), there are expected to be 70,130 new cases of non-Hodgkin's lymphoma diagnosed and approximately 18,940 deaths in the United States in 2012. Non-Hodgkin's lymphoma is defined as any of a large group of cancers of lymphocytes (white blood cells). Non-Hodgkin's lymphomas can occur at any age and are often marked by lymph nodes that are larger than normal, fever, and weight loss. There are many different types of non-Hodgkin's lymphoma. These types can be divided into aggressive (fast-growing) and indolent or low grade (slow-growing) types, and they can be formed from either B-cells or T-cells. Prognosis and treatment depend on the stage and type of disease.

About ZEVALIN® and the ZEVALIN Therapeutic Regimen

ZEVALIN (ibritumomab tiuxetan) injection for intravenous use, is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL). ZEVALIN is also indicated for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma who achieve a partial or complete response to first-line chemotherapy.

1 2 3 4 5 Next › Last »